Precigen, Inc. is a biopharmaceutical company developing gene and cell therapies for immuno-oncology, autoimmune conditions, and infectious diseases. The company's main platforms include AdenoVerse, which uses modified adenoviruses to deliver therapeutic agents and vaccine components, and UltraCAR-T, which engineers T cells to target cancer cells. Its pipeline includes multiple early-stage programs utilizing these platforms to treat cancers such as ovarian cancer and leukemia, as well as a viral-induced respiratory condition, along with an electroporation device for cell engineering applications.

entry readiness 57 · MODERATE · exit proximity 0

Value area 5.04–8.00 · 33% of 120d volume overhead · moderate overhead